Azitra, Inc. - $AZTR STOCK NEWS

Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced positive preclinical data for ATR-04, aimed at treating EGFR inhibitor-induced dermal toxicity. This condition affects about 150,000 patients in the US. The data, presented at the Society of Investigative Dermatology 2024 Annual Meeting, showed ATR-04 reducing methicillin-resistant S. aureus (MRSA) by 99% in ex vivo pig skin and reducing the pro-inflammatory cytokine IL-36γ by 75% in treated human skin models. Additionally, ATR-04 increased human beta defensin 18-fold compared to the vehicle in human skin models. These results support an upcoming IND application to the FDA for a Phase 1b trial in patients undergoing EGFR inhibitors with dermal toxicity.

Azitra, Inc. announces positive preclinical data of ATR-12 and clinical design in Netherton Syndrome presented at the ASGCT Annual Meeting. ATR-12 inhibits key protease driving Netherton syndrome, delivers LEKTI more effectively than topical application, reduces pro-inflammatory cytokine IL-36g, is safe in minipigs, and shows promising results for a Phase 1b study. The study aims to evaluate safety, efficacy, and skin pharmacokinetics of ATR-12 in Netherton syndrome patients.

Azitra, Inc. (NYSE American: AZTR) reported financial results for Q1 2024, showcasing advancement in clinical trials and pre-IND meetings. The company strengthened its IP portfolio, completed a public offering, and progressed in partnership discussions. With a focus on dermatology treatments, Azitra aims to revolutionize severe skin condition treatments, delivering value to shareholders. Financially, the company saw an increase in R&D and G&A expenses, with a net loss of $2.9 million for Q1 2024.

Azitra, Inc. announces new preclinical data to be presented at the American Society of Gene and Cell Therapy Meeting, showcasing the potential of ATR-12 for Netherton syndrome treatment. The data highlights significant reductions in IL-36g and protease activity, as well as enhanced delivery of LEKTI compared to topical application alone.

Azitra, Inc. (NYSE American: AZTR) is set to present new preclinical data at three upcoming scientific conferences in May 2024 focusing on innovative therapies for precision dermatology. The presentations will cover promising treatments for serious skin diseases using engineered Staphylococcus epidermidis strains.

Azitra, Inc. (NYSE American: AZTR) reported financial results for FY 2023, highlighting an IPO that raised $7.5 million and IND clearance for ATR-12. The company advanced multiple clinical trials, strengthened IP portfolio, and engaged in strategic partnerships.

Azitra, Inc. (AZTR) completes a public offering of 16,667,000 shares of common stock at $0.30 per share, raising approximately $5 million. The Company plans to use the proceeds for clinical trials, product development, research, manufacturing, and general corporate purposes.

Azitra, Inc. (AZTR) announces the pricing of a public offering of 16,667,000 shares of common stock at $0.30 per share, generating approximately $5 million in gross proceeds. The Company plans to use the funds for clinical trials, product development, research, manufacturing, and general corporate purposes. The offering is expected to close on February 16, 2024.

Azitra, Inc. (NYSE American: AZTR) has been granted a patent for a strain of Staphylococcus epidermidis to treat ichthyosis vulgaris, a chronic skin disease with no FDA-approved treatment option affecting 1.3 million people in the US. This reinforces Azitra's commitment to precision dermatology and expands its intellectual property portfolio. The company is developing live biotherapeutic product candidates for IV, addressing the disease pathophysiology by delivering filaggrin to the skin.